Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Rosiglitazone Does Not Harm Bone Healing If Combined With Metformin In Rats
Taking the diabetes medications metformin and rosiglitazone together reverses the adverse effects on bone of rosiglitazone treatment alone in an experimental model, according to a new study done in rats. The results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
generic viagra online
Lilly To Unveil More Than 30 Studies At Premier Lung Cancer Meeting
Eli Lilly and Company continues to lead the way in advancing lung cancer treatment. On the heels of new FDA and European Commission approvals for ALIMTA((R)) (pemetrexed for injection) as a treatment for nonsquamous non-small cell lung cancer (NSCLC) in the maintenance setting, the company will release findings from more than 30 lung cancer studies at the 13th World Conference on Lung Cancer (WCLC) in San Francisco, Calif., from July 31 to Aug. 4, 2009. WCLC is sponsored by the International Association for the Study of Lung Cancer. Data will feature Lilly"s ALIMTA and GEMZAR((R)) (gemcitabine HCl for injection).
News of the day
New Cases Of Alzheimer's And Dementia Continue To Rise, Even In The 'Oldest Old'
The number of people with Alzheimer"s and dementia - both new cases and
Medical Devices

Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict From Abbott Laboratories

Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit. "We are pleased that the jury has ruled in our favor in the patent litigation case against Abbott," said Kim Taylor, President, Centocor Ortho Biotech Inc. The patent in question relates to the company"s anti-TNF class of arthritis treatments, and is co-owned by New York University and Centocor, for which Centocor is the exclusive licensee. "We are particularly gratified that the jury recognized our valuable intellectual property, finding our patent both valid and infringed. We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatment for patients with a number of immune mediated inflammatory diseases," Taylor added. Centocor Ortho Biotech Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009